Lifespan Vision Ventures has invested CHF 10 million in TECregen's seed financing round to support the development of biologics aimed at rejuvenating thymic function and enhancing immune resilience.
Target Information
TECregen is at the forefront of developing next-generation biologics aimed at rejuvenating thymic epithelial cells (TECs) to restore and enhance thymic function. The company addresses the increase in age-related thymic involution, which weakens T-cell production, leading to a decline in immune resilience. Through its innovative regenerative biologic platform, TECregen seeks to combat age-related immune decline, enhancing the body’s ability to respond to illnesses and maintain a robust immune system.
The advancements made by TECregen have the potential to revolutionize immunotherapy, particularly for individuals whose immune response has been compromised due to aging or other medical interventions, such as cytotoxic therapy or transplantation.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology sector in Switzerland, where TECregen operates, is known for its strong emphasis on innovation and quality, leveraging a well-established ecosystem of research institutions and pharmaceutical co
Similar Deals
Lifespan Vision Ventures
invested in
TECregen
in 2026
in a Seed Stage deal
Disclosed details
Transaction Size: $10M